EVALUATION OF MINIMAL RESIDUAL DISEASE IN HIGH-RISK CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA USING AN IMMUNOLOGICAL APPROACH DURING COMPLETE REMISSION

被引:0
|
作者
CONSOLINI, R
SCAMARDELLA, F
LEGITIMO, A
PUTTI, C
GRANCHI, D
PAOLUCCI, P
LIPPI, A
GUAZZELLI, C
ACQUAVIVA, A
ROSANDA, C
BASSO, G
MACCHIA, P
机构
[1] UNIV PADUA, DIPARTIMENTO PEDIAT, I-35100 PADUA, ITALY
[2] UNIV BOLOGNA, PEDIAT CLIN 3, I-40126 BOLOGNA, ITALY
[3] UNIV FLORENCE, PEDIAT CLIN, I-50121 FLORENCE, ITALY
[4] UNIV SIENA, IST CLIN PEDIAT, I-53100 SIENA, ITALY
[5] IST GIOVANNA GASLINI, GENOA, ITALY
关键词
MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; COMPLETE REMISSION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Sensitive methods for detecting residual disease may complement conventional morphology while monitoring the response to treatment in leukemia patients. Methods. We studied minimal residual disease (MRD) by selecting via a colony assay a peripheral blood (PB) cell population enriched in putative malignant cells and detecting occult leukemic cells by double immunologic analysis performed on colonyforming cells (CFC). Using this combined technique we assayed the PB of high risk children with acute lymphoblastic leukemia (ALL) in order to demonstrate possible differences in <<the residual tumor cell burden>> among leukemia patients and to correlate these with a 3-year clinical follow-up. Results. In all 22 patients positive results were obtained for up to 18 months following induction chemotherapy at times of apparent hematologic remission. Common ALL (cALL) patients exhibited a mean of 9.6% cAlla+ cells (range: 2% to 30%), whereas cALL antigen (cALLA) and cALLA/Tdt or CDla/Tdt combination were never found in the colonies derived from healthy individuals. Six out of 22 cALL patients expressed a mean of 16.5% cALLA+/Tdt+ CFC (range: 2% to 35%). Five TALL children presented a mean of 24% CD1a/Tdt+ cells (range: 8% to 44%). Extensive follow-up indicates a correlation between the percentage of CFC Tdt+/lymphoid marker+ cells (more than 10%) and subsequent clinical relapse. In one patient relapse occurred after 16 months with a dramatic increase in the number of leukemic cells. In contrast, the decline in malignant cells, observed in two cases, predicted a favourable course. Five patients tested before autologous bone marrow transplantation (ABMT) presented high number of positive cells and relapsed at various times. Conclusions. We conclude that this approach to the study of MRD could be valuable in monitoring the efficacy of chemotherapy, as well in evaluating the quality of purged marrow.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 50 条
  • [31] Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease
    Bourlon, Christianne
    Lacayo-Lenero, Dennis
    Inclan-Alarcon, Sergio I.
    Demichelis-Gomez, Roberta
    CURRENT ONCOLOGY REPORTS, 2018, 20 (04)
  • [32] Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis
    A Ruggeri
    G Michel
    J-H Dalle
    M Caniglia
    F Locatelli
    A Campos
    C D de Heredia
    M Mohty
    J M P Hurtado
    M Bierings
    H Bittencourt
    M Mauad
    D Purtill
    R Cunha
    N Kabbara
    E Gluckman
    M Labopin
    C Peters
    V Rocha
    Leukemia, 2012, 26 : 2455 - 2461
  • [33] Detection of minimal residual disease in childhood acute lymphoblastic leukemia: technology and clinical applications
    Pawlowska, Anna B.
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2005, 9 (04): : 178 - 182
  • [34] Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia
    Vinhas, Ester
    Lucena-Silva, Norma
    Pedrosa, Francisco
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2018, 94 (01) : 94 - 99
  • [35] Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre-transplant minimal residual disease on outcomes in high-risk acute lymphoblastic leukemia patients in complete remission
    Zhao, Xiaoyan
    Xu, Ziwei
    Li, Ziying
    Zhou, Xi
    Hu, Yu
    Wang, Huafang
    CANCER MEDICINE, 2024, 13 (01):
  • [36] Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome
    B Gruhn
    S Hongeng
    H Yi
    ML Hancock
    JE Rubnitz
    GAM Neale
    GR Kitchingman
    Leukemia, 1998, 12 : 675 - 681
  • [37] High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation
    G M Marshall
    L Dalla Pozza
    R Sutton
    A Ng
    H A de Groot-Kruseman
    V H van der Velden
    N C Venn
    H van den Berg
    E S J M de Bont
    R Maarten Egeler
    P M Hoogerbrugge
    G J L Kaspers
    M B Bierings
    E van der Schoot
    J van Dongen
    T Law
    S Cross
    H Mueller
    V de Haas
    M Haber
    T Révész
    F Alvaro
    R Suppiah
    M D Norris
    R Pieters
    Leukemia, 2013, 27 : 1497 - 1503
  • [38] Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome
    Gruhn, B
    Hongeng, S
    Yi, H
    Hancock, ML
    Rubnitz, JE
    Neale, GAM
    Kitchingman, GR
    LEUKEMIA, 1998, 12 (05) : 675 - 681
  • [39] Immunologic minimal residual disease detection in acute lymphoblastic leukemia: A comparative approach to molecular testing
    Coustan-Smith, Elaine
    Campana, Dario
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2010, 23 (03) : 347 - 358
  • [40] Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation
    Lankester, A. C.
    Bierings, M. B.
    van Wering, E. R.
    Wijkhuijs, A. J. M.
    de Weger, R. A.
    Wijnen, J. T.
    Vossen, J. M.
    Versluys, B.
    Egeler, R. M.
    van Tol, M. J. D.
    Putter, H.
    Revesz, T.
    van Dongen, J. J. M.
    van der Velden, V. H. J.
    Schilham, M. W.
    LEUKEMIA, 2010, 24 (08) : 1462 - 1469